Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ADUS vs DBVT vs ALKS vs HCSG vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Care Facilities
Drug Manufacturers - Specialty & Generic
ADUS vs DBVT vs ALKS vs HCSG vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Care Facilities | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.81B | $1712.35T | $5.90B | $1.60B | $1.61B |
| Revenue (TTM) | $1.45B | $0.00 | $1.56B | $1.84B | $4.18B |
| Net Income (TTM) | $100M | $-168M | $153M | $59M | $-1.82B |
| Gross Margin | 32.5% | — | 65.4% | 13.3% | 34.2% |
| Operating Margin | 9.8% | — | 12.3% | 3.0% | -4.1% |
| Forward P/E | 14.1x | — | 24.8x | 20.8x | 5.6x |
| Total Debt | $209M | $22M | $70M | $25M | $3.97B |
| Cash & Equiv. | $82M | $194M | $1.12B | $161M | $532M |
ADUS vs DBVT vs ALKS vs HCSG vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 100 | 98.3 | -1.7% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADUS vs DBVT vs ALKS vs HCSG vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ADUS has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.58
- Rev growth 23.2%, EPS growth 23.2%, 3Y rev CAGR 14.4%
- 399.9% 10Y total return vs ALKS's -11.0%
- 23.2% revenue growth vs DBVT's -100.0%
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs PRGO's -51.2%
ALKS is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs PRGO's -43.5%
HCSG is the clearest fit if your priority is efficiency.
- 7.3% ROA vs DBVT's -89.0%
PRGO is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (5.6x vs 20.8x)
- 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.2% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (5.6x vs 20.8x) | |
| Quality / Margins | 9.8% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.58 vs DBVT's 1.26 | |
| Dividends | 9.8% yield; 10-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs PRGO's -51.2% | |
| Efficiency (ROA) | 7.3% ROA vs DBVT's -89.0% |
ADUS vs DBVT vs ALKS vs HCSG vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ADUS vs DBVT vs ALKS vs HCSG vs PRGO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
HCSG leads 2 • PRGO leads 1 • ADUS leads 0 • DBVT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO and DBVT operate at a comparable scale, with $4.2B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.4B | $0 | $1.6B | $1.8B | $4.2B |
| EBITDAEarnings before interest/tax | $159M | -$112M | $212M | $72M | $58M |
| Net IncomeAfter-tax profit | $100M | -$168M | $153M | $59M | -$1.8B |
| Free Cash FlowCash after capex | $137M | -$151M | $392M | $139M | $108M |
| Gross MarginGross profit ÷ Revenue | +32.5% | — | +65.4% | +13.3% | +34.2% |
| Operating MarginEBIT ÷ Revenue | +9.8% | — | +12.3% | +3.0% | -4.1% |
| Net MarginNet income ÷ Revenue | +6.9% | — | +9.8% | +3.2% | -43.5% |
| FCF MarginFCF ÷ Revenue | +9.5% | — | +25.1% | +7.6% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.7% | — | +28.2% | +6.6% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.2% | +91.5% | -4.1% | +175.0% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 18.7x trailing earnings, ADUS trades at a 32% valuation discount to HCSG's 27.5x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than HCSG's 22.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.8B | $1712.35T | $5.9B | $1.6B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $1712.35T | $4.9B | $1.5B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 18.67x | -0.76x | 24.76x | 27.54x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.12x | — | — | 20.83x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 12.52x | — | 17.25x | 22.38x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | — | 4.00x | 0.87x | 0.38x |
| Price / BookPrice ÷ Book value/share | 1.65x | 0.66x | 3.28x | 3.19x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 17.48x | — | 12.28x | 11.49x | 11.12x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HCSG delivers a 11.8% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ADUS scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.3% | -130.2% | +8.8% | +11.8% | -50.7% |
| ROA (TTM)Return on assets | +7.0% | -89.0% | +5.4% | +7.3% | -19.8% |
| ROICReturn on invested capital | +8.8% | — | +18.9% | +9.0% | +3.7% |
| ROCEReturn on capital employed | +10.9% | -145.7% | +14.2% | +7.7% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 7 | 7 | 4 |
| Debt / EquityFinancial leverage | 0.19x | 0.13x | 0.04x | 0.05x | 1.35x |
| Net DebtTotal debt minus cash | $127M | -$172M | -$1.0B | -$136M | $3.4B |
| Cash & Equiv.Liquid assets | $82M | $194M | $1.1B | $161M | $532M |
| Total DebtShort + long-term debt | $209M | $22M | $70M | $25M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 14.45x | -189.82x | 32.30x | 33.02x | -7.20x |
Total Returns (Dividends Reinvested)
HCSG leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.7% | +4.9% | +25.3% | +28.6% | -13.5% |
| 1-Year ReturnPast 12 months | -13.4% | +110.4% | +16.5% | +55.8% | -51.2% |
| 3-Year ReturnCumulative with dividends | +16.3% | +19.7% | +14.5% | +48.6% | -58.1% |
| 5-Year ReturnCumulative with dividends | +0.0% | -69.1% | +60.9% | -21.1% | -60.1% |
| 10-Year ReturnCumulative with dividends | +399.9% | -87.0% | -11.0% | -26.8% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +5.2% | +6.2% | +4.6% | +14.1% | -25.2% |
Risk & Volatility
Evenly matched — ADUS and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADUS is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.58x | 1.26x | 1.06x | 1.12x | 1.18x |
| 52-Week HighHighest price in past year | $124.44 | $26.18 | $36.60 | $24.39 | $28.44 |
| 52-Week LowLowest price in past year | $90.89 | $7.53 | $25.17 | $12.66 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +78.2% | +76.3% | +96.7% | +91.5% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 48.1 | 60.2 | 61.8 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 236K | 252K | 2.3M | 676K | 3.4M |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ADUS as "Buy", DBVT as "Buy", ALKS as "Buy", HCSG as "Hold", PRGO as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 9.8% for HCSG (target: $25). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $128.67 | $46.33 | $44.00 | $24.50 | $20.00 |
| # AnalystsCovering analysts | 15 | 15 | 28 | 15 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | 2 | 0 | 0 | 20 | 10 |
| Dividend / ShareAnnual DPS | — | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +3.9% | 0.0% |
ALKS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HCSG leads in 2 (Total Returns, Analyst Outlook). 1 tied.
ADUS vs DBVT vs ALKS vs HCSG vs PRGO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ADUS or DBVT or ALKS or HCSG or PRGO a better buy right now?
For growth investors, Addus HomeCare Corporation (ADUS) is the stronger pick with 23.
2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Addus HomeCare Corporation (ADUS) offers the better valuation at 18. 7x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Addus HomeCare Corporation (ADUS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ADUS or DBVT or ALKS or HCSG or PRGO?
On trailing P/E, Addus HomeCare Corporation (ADUS) is the cheapest at 18.
7x versus Healthcare Services Group, Inc. at 27. 5x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ADUS or DBVT or ALKS or HCSG or PRGO?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ADUS returned +399. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ADUS or DBVT or ALKS or HCSG or PRGO?
By beta (market sensitivity over 5 years), Addus HomeCare Corporation (ADUS) is the lower-risk stock at 0.
58β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 119% more volatile than ADUS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — ADUS or DBVT or ALKS or HCSG or PRGO?
By revenue growth (latest reported year), Addus HomeCare Corporation (ADUS) is pulling ahead at 23.
2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ADUS leads at 14. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ADUS or DBVT or ALKS or HCSG or PRGO?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ADUS or DBVT or ALKS or HCSG or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 20. 8x for Healthcare Services Group, Inc. — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — ADUS or DBVT or ALKS or HCSG or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. ADUS, DBVT, ALKS, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is ADUS or DBVT or ALKS or HCSG or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
58), +399. 9% 10Y return). Both have compounded well over 10 years (ADUS: +399. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ADUS and DBVT and ALKS and HCSG and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ADUS is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; HCSG is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while ADUS, DBVT, ALKS, HCSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.